Malin Corporation Plc

Board/Management Information • Jan 16, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1961N

Malin Corporation PLC

16 January 2019

Malin Corporation plc

("Malin")

Immunocore names David Berman as

Head of Research & Development

-     Malin owns approximately 10% of Immunocore, a Malin Priority Portfolio Asset -

Dublin-Ireland, 16 January 2019: Malin Corporation plc (ISE:MLC), a company investing in highly innovative life sciences companies, is pleased to note that Immunocore has named David Berman as its new Head of Research & Development (R&D).

David joined Immunocore in September 2018 to advance Immunocore's lead asset, IMCgp100, towards commercialisation and progress Immuocore's growing pipeline of T Cell Receptor (TCR) candidates through clinical development. Prior to joining Immunocore, David was most recently Senior Vice President and Head of the AstraZeneca Immuno-oncology (IO) Franchise, responsible for the strategic development and execution of its late-stage IO programme. David also previously served as Head of the early-stage oncology progamme at MedImmune, and Head of the Immuno-oncology exploratory development team at Bristol-Myers Squibb.

"David Berman is an established leader in the field of immuno-oncology and his appointment as Head of R&D of Immunocore further demonstrates the potential of the company's technology pipeline" said Jean-Michel Cosséry, Non-Executive Director of Malin and Malin's Immunocore Board designate. "With David's exceptional expertise in developing novel IO targets and combinations, he is ideally qualified to drive Immunocore's growing pipeline of TCR candidates through clinical development and commercialisation."

Malin owns approximately 10% of Immunocore and carried its investment in Immunocore at €85.1 million at 30 June 2018 in its portfolio fair value estimate under International Private Equity Valuation guidelines.

A copy of Immunocore's press release is available to view here: https://www.immunocore.com/news-hub/news 

ENDS

For further information, please contact:

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Jonathan Birt

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Ireland PR)           

Eavan Gannon                                              

Tel: +353 87 236 5973                            

malin@powerscourt-group.com                                                                          

Davy Corporate Finance (ESM Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

About Malin Corporation plc

Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDSFFEEIFUSEFF